Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Celularity Inc.
Headquarters: Florham Park, NJ, United States of America
Website: http://www.celularity.com
Year Founded: 2016
Status: Public
Industry Sector: CommercialServices
CEO: Robert Joseph Hariri Gordon, MD, PhD
Number Of Employees: N/A
Enterprise Value: N/A
PE Ratio: -0.98
Exchange/Ticker 1: NASDAQ:CELU
Exchange/Ticker 2: N/A
Latest Market Cap: $36,425,800
BioCentury | Aug 7, 2024
Management Tracks
Flagship’s Quotient names co-founder Campbell CSO
Plus: Cellectis hires Kilcoyne and more from Helio, Sapphiros, Pharmanovia, the ADA and Outcome Capital
BioCentury | Aug 29, 2023
Product Development
Aug. 29 Quick Takes: Phase III miss in DMD for FibroGen
Plus: Expanded label for BMS’s Reblozyl, Apellis restructuring and updates from Inhibrx, CEPI, iCamuno, Regeneron, Nevia
BioCentury | Feb 28, 2023
Product Development
NK cell companies agree they differ, but not on what features matter most
Fate’s pipeline reprioritization raises questions about iPSC-derived NK cells
BioCentury | Jan 6, 2023
Management Tracks
Singhal to lead development at Biogen as company splits R&D
Plus: Baumal named CMO at Apellis, and updates from Pheast, Sofinnova Partners, GE, Lexeo and more
BioCentury | Nov 18, 2022
Product Development
Oncolytic virus combinations move beyond checkpoint inhibitors
SITC updates suggest the next wave of oncolytic viruses will be paired with bispecifics, cell therapies
BioCentury | Oct 6, 2022
Management Tracks
LifeMine rounds out team with Stahl, Plamondon
Plus Theolytics adds Actelion vet Oakley as CFO, and updates from Capricorn, Cambrian,
BioCentury | Oct 4, 2022
Management Tracks
Sause named CEO of Roche Diagnostics
Plus Kranzler becomes CEO of Urica, and updates from Pharus, Celularity, Cerevance and more
BioCentury | May 20, 2022
Product Development
Next-gen NK cell enhancements in the clinic
Companies are turning to tumor targeting, IL-15 expression and alternate cell sourcing to boost the potency and longevity of NK cell therapies
BioCentury | Nov 19, 2021
Management Tracks
Zhang becomes CSO at Aspen
Plus: PhaseBio, LifeSprout, Rejuveron and Aerami
BioCentury | Sep 17, 2021
Management Tracks
Barnett joins Immunovant as CFO
Plus: Celularity, Autolus, Kyverna, AM-Pharma, Saniona and more
Items per page:
1 - 10 of 27